Disease relevance of Efosite-Al

• PURPOSE: Because docetaxel (Taxotere, RP 56976; Rhone-Poulenc Rorer, Antony, France) appeared to be active against breast cancer in phase I trials, we performed this phase II study [1].
• PURPOSE: We conducted a phase II study to determine the response and toxicity of docetaxel (Taxotere; Rhône-Poulenc Rorer Pharmaceuticals, Inc, Collegeville, PA) in chemotherapy-naive patients with advanced non-small-cell lung cancer [2].
• PURPOSE: We conducted a phase II study to determine the response to and toxicity of docetaxel (Taxotere; Rhône-Poulenc Rorer Pharmaceuticals, Inc, Collegeville, PA) in patients with advanced non-small-cell lung cancer refractory to prior platinum-containing chemotherapy (PCC) regimens [3].
• PURPOSE: We conducted a phase II study designed to evaluate the activity, safety, and tolerability of docetaxel (Taxotere: Rhône-Poulenc Rorer Pharmaceuticals Inc, Collegeville, PA) in patients with advanced, incurable, or recurrent squamous cell carcinoma of the head and neck (SCCHN) who had not received prior palliative chemotherapy [4].
• [1(S)-Aminoethyl][(2RS)2-carboxy-1-octyl]phosphinic acid (I), previously shown to bind tightly to Enterococcus faecalis and Salmonella typhimurium D-alanine:D-alanine ligases following phosphorylation Parsons, Patchett, Bull, Schoen, Taub, Davidson, Combs, Springer, Gadebusch, Weissberger, Valiant, Mellin & Busch (1988) J [5].

High impact information on Efosite-Al

• PURPOSE: To evaluate the efficacy and toxicity of combination and sequential dose-dense chemotherapy with doxorubicin and docetaxel (Taxotere; Rhône-Poulenc Rorer, Collegeville, PA) as primary chemotherapy of breast cancer [6].
• PURPOSE: Docetaxel (Taxotere, Rhone-Poulenc Rorer, Antony, France) and cisplatin are two of the most active single agents used in the treatment of non-small-cell lung cancer (NSCLC) [7].
• Docetaxel (Taxotere; Rhône-Poulenc Rorer, Paris, France) 75 mg/m2 was combined with cisplatin 75 mg/m2 every third week [8].
• PURPOSE: This phase I study of Taxotere (RP 56976, NSC 628503; docetaxel, Rhône-Poulenc Rorer, Antony, France) was undertaken to determine the maximum-tolerated dose (MTD), toxic effects, and basic pharmacokinetics of a day-1 and -8 schedule of this novel semisynthetic product related to Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) [9].
• We investigated whether a low dose of low-molecular-weight heparin-enoxaparin (Clexane, Rhône-Poulenc Rorer, France)-ameliorates the inflammatory response in two models of experimental colitis [10].

Chemical compound and disease context of Efosite-Al

• In patients with advanced cancers, gemcitabine and docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) can be administered together at 80% to 100% of their single-agent doses on days 1 and 8 of an every-3-week cycle without undue toxicity [11].
• Several groups have reported significant efficacy and minimal toxicity in patients with hormone-refractory disease receiving estramustine plus docetaxel (Taxotere; Rhône-Poulenc Rorer, Collegeville, PA) [12].
• In a prospective multicenter trial, 279 patients with metastatic colorectal cancer who had failed 5-fluorouracil therapy were randomized 2:1 to receive either best supportive care (BSC) plus treatment with the topoisomerase I inhibitor, irinotecan (CPT-11; Rhône-Poulenc Rorer, Antony, France), at a dose of 350 mg/m2 every 3 weeks or BSC alone [13].
• A low dose (1.25 mg) of indapamide (Lozol, Rhône-Poulenc Rorer Pharmaceuticals, Collegeville, PA) was evaluated in 222 elderly patients (> or = 50 years) with mild to moderate essential hypertension in a multicenter, randomized, double-blind, parallel-group clinical trial [14].
• A double-blind safety and efficacy dose-ranging study was conducted with a new, once-daily, extended-release (XR) diltiazem hydrochloride formulation (Dilacor XR, Rhône-Poulenc Rorer, Collegeville, PA) in 189 patients with chronic stable angina pectoris [15].

Biological context of Efosite-Al

• Docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) is a hemisynthetic derivative from European yew that inhibits tubulin depolymerization and enhances the formation of microtubule bundle aggregates, causing cell death [16].
• Occupational exposure to fosetyl-Al fungicide during spraying of ornamentals in greenhouses [17].
• A kinetic study of the chemical hydrolysis of isoxaflutole [5-cyclopropyl-4-(2-methanesulfonyl-4-trifluoromethylbenzoyl)is oxazol e (IFT)], a new herbicide recently developed by Rhône-Poulenc Agro, in buffered, sterile aqueous solutions was carried out in the dark at 295, 308, and 323 K and at nine pH values between 1.8 and 10 [18].
• Our early experience of using Valiant in 28 patients with a range of pathologies is described [19].
• Seattle Genetics is developing SGN-10 (BR96-SCIT), a single-chain immunotoxin (SCIT) under license from Bristol-Myers Squibb (BMS), as both a monotherapy and in combination with Taxotere (Rhône-Poulenc Rorer) for the potential treatment for cancer [308773] [20].

Anatomical context of Efosite-Al

• Docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) is a semisynthetic taxoid that is an inhibitor of microtubule depolymerization [21].
• In each group, the flat dentin surface was treated with the assigned adhesive cement with a Teflon mold, followed by condensation of amalgam (Valiant PhD) onto it [22].
• These results suggest a metabolic activation of peroxidase isoenzyme B5 as a consequence of fosetyl-A1 treatment, probably due to an acidification of the vacuole [23].
• An in-vitro study of marginal leakage around class V restorations, prepared in freshly extracted upper central incisors, tested two types of high copper amalgam: spherical high copper amalgam (Tytin) and spherical high copper amalgam containing palladium (Valiant) [24].

Associations of Efosite-Al with other chemical compounds

• Patients received estramustine phosphate 280 mg orally every 6 hours for a total of five doses (24-hour exposure), docetaxel (Taxotere; Rhône-Poulenc Rorer, Collegeville, PA) 70 mg/m2 intravenously over 1 hour, coumadin 2 mg orally every day, and dexamethasone as premedication for docetaxel [25].
• The levels of phosphorous acid residues in apples after foliar fertilization with P fertilizers and after treatment with a phosphonate fungicide (Fosetyl-Al) were determined and compared [26].
• Ground occlusal dentin surfaces of 140 formaldehyde-treated human molars were used to study shear strengths of different adhesive bonds (40: Syntac/Variolink, 40: Amalgambond Plus (AP), 40: AP+microfibre, and 20: Amalcoden) to a spherical high-copper amalgam (Valiant, Ivoclar NA) [27].
• Wear ranking from the least to the most volumetric wear was as follows: high copper unicompositional alloy, Tytin (T) < high copper admixed alloy, Valiant PhD (V) < microfilled composite resin, Silux Plus (S) < gallium alloy, Galloy (G) < heavily filled composite resin, Z100 (Z) < hybrid composite resin, P50 (P) [28].
• RESULTS: Fracture toughness values obtained were as follows: Fluorocore (composite resin; Caulk, Milford, DE), 1.54 MN.m-1.5; Ti-Core (composite resin and titanium; Essential Dental Systems, New York, NY), 1.34 MN.m-1.5; Valiant Ph.D. (amalgam; Caulk), 1.29 MN.m-1.5; and Coreshade Glass Ionomer Base Cement (Shofu Inc, Kyota, Japan), 0.55 MN.m-1 [29].

Gene context of Efosite-Al

• This impact has perhaps been greatest for treatment of severe chronic neutropenia (SCN) conditions for which there were no predictably effective treatment before the availability of these growth factors, particularly r-metHuG-CSF (Filgrastim, Amgen Inc, Thousand Oaks, CA; or Lenograstim, Rhone-Poulenc Rorer, Milan, Italy) [30].
• Impact and sliding wear were simulated on the machine, with water as the lubricant, on three metal alloys (Tytin, Valiant Ph.D., Galloy) and three composite resins (Silux Plus, Z100, P50) [31].
• Microbial HTS has been implemented at Rhône-Poulenc Rorer through the development of a dedicated robotic platform [32].
• The three disposables considered here (Gambro Lundia Nova, Cordis HFAK 4 and Rhone Poulenc RP 5) all have clearance of small molecules close to or, for the HFAK 4, just above that of the multipoint though their middle molecular clearance is not quite as good as the multipoint [33].
• MATERIALS AND METHODS: Inlay composites (EOS) were bonded with two different bonding systems (Geristore, All-Bond 2) to high- or low-copper amalgams (Valiant, Agestan) [34].

Analytical, diagnostic and therapeutic context of Efosite-Al

• Rhône-Poulenc to focus biotech work on gene therapy [35].
• The results of recent clinical trials have shown that docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France), like paclitaxel (Taxol; Bristol-Myers Squibb Oncology, Princeton, NJ), has high levels of activity in patients with anthracycline-resistant breast cancer [36].
• Considering the single-agent activity of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) and doxorubicin in breast cancer and their potential non-cross-resistance, several docetaxel/anthracycline-based combination chemotherapies were developed in phase I and II programs for metastatic breast cancer patients [37].
• This report describes the design and status of an ongoing randomized, phase III study of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) as neoadjuvant treatment in patients with stage IIIa/b NSCLC, as well as of two phase II studies of combination neoadjuvant therapies [38].
• Several phase II studies have evaluated docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) at a dose of 100 mg/m2 administered as a 1-hour intravenous infusion every 3 weeks in the second-line treatment of non-small cell lung cancer (NSCLC) [39].

References